mucos
vaccin
shown
elicit
system
mucos
immun
respons
serv
noninvas
conveni
altern
parenter
administr
stronger
capabl
combat
diseas
site
entri
explor
potent
mucos
adjuv
emerg
signific
area
base
continu
necess
amplifi
immun
respons
wide
array
antigen
poorli
immunogen
mucos
site
one
inspir
ocean
chitosanbas
mucos
adjuv
develop
uniqu
advantag
abil
mucos
adhes
distinct
trait
open
junction
allow
paracellular
transport
antigen
good
toler
biocompat
guarante
great
potenti
capit
applic
human
clinic
trial
review
state
art
chitosan
deriv
mucos
adjuv
includ
thermosensit
chitosan
system
mucos
adjuv
newli
develop
author
group
describ
well
clinic
applic
perspect
brief
introduct
mucos
adjuv
chitosan
deriv
robust
immun
potenti
discuss
detail
depth
regard
metabol
safeti
profil
mode
action
preclin
clinic
applic
may
shed
light
massiv
clinic
applic
chitosan
mucos
adjuv
vaccin
arguabl
success
effect
medic
intervent
prevent
infecti
diseas
result
decreas
mortal
extend
life
expect
improv
qualiti
life
million
vaccin
formul
administ
subcutan
intramuscular
inject
accord
record
howev
shortcom
persist
throughout
develop
vaccin
industri
needlestick
injuri
potenti
contamin
need
highli
train
personnel
furthermor
pathogen
invad
bodi
mucos
site
mucos
immun
system
compris
epitheli
cell
mucosaassoci
lymphoid
tissu
malt
lamina
propria
contain
almost
immunocyt
human
bodi
constitut
first
line
defens
infect
unfortun
vaccin
via
inject
fail
achiev
accept
immun
protect
mucos
site
needlefre
vaccin
offer
immens
potenti
term
patient
complianc
eas
administr
attract
great
attent
recent
signific
mucos
immun
potenti
improv
global
health
inspir
research
demonstr
mucos
vaccin
could
attract
altern
parenter
administr
nonetheless
administr
antigen
via
mucos
rout
normal
lead
poor
immunogen
stimul
overcom
live
pathogen
employ
commerci
vaccin
oral
polio
oral
cholera
oral
rotaviru
nasal
influenza
flumist
tm
nasovac
tm
still
retain
potenti
hazard
largescal
applic
henc
ration
design
appropri
adjuv
system
potent
capac
stimul
immun
essenti
modern
manufactur
technolog
oblig
meet
follow
requir
stabil
antigen
acid
alkalin
enzymat
environ
retent
antigen
despit
constant
clearanc
mucos
site
potent
induct
system
mucos
immun
balanc
enhanc
mucos
immun
possibl
immun
toler
use
high
dose
antigen
promis
solut
chitosan
possess
welldefin
properti
includ
biocompat
low
cost
high
level
toler
broad
antibodi
respons
capac
stimul
robust
respons
chitosan
demonstr
distinct
mucoadhes
prolong
antigen
http
elsevi
ltd
right
reserv
retent
time
mucos
site
well
abil
open
tight
junction
epitheli
cell
intensifi
transport
antigen
site
immun
induct
effector
respons
moreov
versatil
chitosan
enabl
divers
formul
chitosanbas
deliveri
system
solut
powder
micronanoparticl
hydrogel
microneedl
patch
meet
variou
need
novel
vaccin
method
recent
research
propos
sever
promis
chitosanbas
formul
highli
suitabl
mucos
adjuv
outstand
safeti
profil
articl
aim
provid
uptod
review
preclin
clinic
applic
novel
adjuv
system
although
chitosan
investig
mani
year
basic
materi
mucos
adjuv
yet
present
market
vaccin
formul
main
obstacl
may
lack
understand
metabol
concern
regard
safeti
issu
henc
comprehens
evalu
metabol
safeti
profil
mode
action
clinic
applic
also
present
follow
section
chitosan
natur
cation
polysaccharid
made
copolym
glucosamin
link
nacetylglucosamin
deriv
partial
deacetyl
chitin
obtain
shell
crustacean
mycelium
fungi
wide
rang
chitosan
polym
avail
divers
molecular
weight
mw
degre
deacetyl
dd
modif
may
impact
solubl
biocompat
mucoadhes
behavior
degrad
thu
influenc
immunogen
et
al
success
show
three
commerci
chitosan
differ
mw
dd
possess
vari
level
adjuv
activ
impur
protein
contamin
chitosan
found
play
minor
role
also
point
divers
adjuv
effect
attribut
singl
factor
rather
interplay
molecular
weight
degre
deacetyl
particl
size
solubl
overcom
poor
solubl
chitosan
neutral
ph
variou
chitosan
deriv
develop
chemic
modif
hydrophil
group
simpli
graft
watersolubl
polym
eg
polyethylen
glycol
derivat
chitosan
enhanc
water
solubl
also
improv
cation
natur
materi
enhanc
interact
antigen
cell
membran
boost
antigen
adsorptionencapsul
cellular
intern
well
facilit
resid
time
mucos
site
among
watersolubl
chitosan
deriv
ntrimethyl
chitosan
tmc
n
ammonium
chitosan
chlorid
htcc
commonli
use
mucos
adjuv
chemic
structur
main
properti
summar
tabl
comprehens
understand
metabol
polym
prerequisit
develop
novel
adjuv
natur
polysaccharid
chitosan
usual
regard
nontox
biolog
compat
polym
vitro
studi
proven
chitosan
degrad
effici
lysozym
result
approxim
decreas
weight
chitosan
hydrogel
within
day
three
enzymat
activ
form
human
chitinas
identifi
investig
degrad
chitosan
deriv
name
acid
mammalian
chitinas
amcas
dinacetylchitobias
chitotriosidas
found
gastrointestin
tract
liver
plasma
respect
recent
research
reveal
degrad
kinet
depend
strongli
molecular
weight
degre
deacetyl
typic
higher
enzymereact
rate
found
degrad
highmw
chitosan
lowdd
chitosan
degrad
rapidli
remain
acetyl
group
may
serv
essenti
contact
activ
site
chitosanas
tmc
degrad
lysozym
similar
rate
nativ
chitosan
degrad
rate
independ
ph
studi
vivo
degrad
chitosan
underw
partial
digest
uptak
gastrointestin
tract
deposit
tissu
circul
plasma
eventu
elimin
bodi
limit
data
degrad
distribut
chitosan
present
difficulti
track
trace
amount
chitosan
live
bodi
howev
conclus
deduc
first
vivo
degrad
distribut
chitosan
larg
depend
molecular
weight
fitclabel
chitosan
small
molecular
weight
kda
absorb
gastrointestin
tract
give
signific
plasma
concentr
howev
chitosan
mw
higher
kda
similar
dd
excret
fece
without
uptak
indic
chitosan
polym
chitosan
oligosaccharid
could
adsorb
gut
addit
optim
mw
chitosan
renal
clearanc
estim
kda
mw
adsorb
chitosan
oligom
larger
would
undergo
biodegrad
failur
intranas
formul
clinic
trial
suggest
toxic
may
caus
uptak
degrad
product
brain
irrit
nasal
mucosa
degrad
may
lead
seriou
local
symptom
neurolog
disord
bell
palsi
facial
nerv
paralysi
caus
intranas
administr
heatlabil
enterotoxin
use
adjuv
case
chitosanbas
mucos
adjuv
understand
distribut
degrad
chitosan
vital
import
dispel
safeti
concern
recent
smith
et
al
point
highdd
chitosan
degrad
much
slowli
local
ph
nasal
caviti
might
guarante
administ
chitosan
would
clear
mucociliari
movement
swallow
alimentari
tract
might
protect
bodi
sever
advers
effect
toxicolog
respons
chitosan
high
dd
probabl
serv
ideal
raw
materi
develop
intranas
vaccin
result
concentr
metabol
behavior
chitosan
polym
hand
metabol
chitosan
powder
smaller
particl
may
differ
stori
although
trimethylchitosan
oligomersdna
nanoparticl
shown
absorb
gastric
tract
still
insuffici
evid
support
deduct
chitosan
formul
would
degrad
similar
manner
regard
safeti
profil
chitosan
cytotox
depend
concentr
molecular
weight
degre
deacetyl
halfmaxim
inhibitori
concentr
mgml
cell
model
addit
differ
form
chitosan
shown
similar
cytotox
effect
number
studi
shown
good
toler
safeti
perform
chitosan
administ
via
oral
rout
tabl
current
employ
chitosan
deriv
mucos
permeat
enhanc
vivo
advers
effect
occur
mous
rat
model
oral
intak
chitosan
dose
gkgday
month
addit
relev
clinic
sign
found
healthi
human
volunt
take
oral
dose
gday
moreov
peopl
shrimp
allergi
shown
allerg
reaction
oral
administr
shellfishderiv
glucosamin
archimed
group
conduct
larg
number
preclin
clinic
studi
chitosan
administ
via
intranas
rout
conclud
chitosan
could
well
toler
advers
effect
mild
symptom
erythema
itchi
nose
rhinorrhea
sore
throat
view
fact
chitosan
gener
thought
biodegrad
biocompat
biomateri
minor
toxic
offer
potenti
safe
pharmaceut
materi
clinic
vaccin
formul
consequ
raw
materi
select
care
regard
molecular
weight
degre
deacetyl
puriti
moreov
worth
notic
physiochem
biolog
properti
chitosan
also
influenc
origin
raw
materi
manufactur
procedur
even
season
weather
batchtobatch
consist
stabil
raw
materi
challeng
select
chitosanbas
adjuv
clinic
trial
greatest
differ
vaccin
adjuv
drug
deliveri
system
vaccin
administ
healthi
peopl
especi
popul
high
risk
contract
infecti
diseas
infant
elderli
mean
side
effect
must
avoid
nevertheless
truth
adjuv
nearer
get
kill
effect
appropri
level
inflammatori
respons
undesir
drugdeliveri
system
obligatori
immun
stimul
futur
research
must
manag
balanc
toxic
adjuvant
order
advanc
clinic
applic
chitosanbas
mucos
adjuv
chitosanbas
formul
found
orchestr
cellular
humor
respons
repres
promis
candid
adjuv
deliveri
system
mucos
vaccin
therefor
essenti
understand
mechan
mucos
immun
mode
action
chitosanbas
adjuv
ration
design
chitosanbas
adjuv
system
profound
abil
stimul
immun
distinct
safeti
perform
numer
studi
demonstr
potent
induct
cellular
respons
activ
innat
immun
system
posit
effect
mucos
adjuvant
section
gener
strategi
develop
chitosan
promis
mucos
adjuv
address
detail
refer
recent
report
innat
immun
system
initi
immedi
consist
respons
toward
infect
also
directli
trigger
adapt
immun
system
recognit
innat
immun
system
requir
activ
pattern
recognit
receptor
prr
tolllik
receptor
tlr
one
membranebound
prr
nucleotidebind
domain
leucinerich
repeat
contain
receptor
nlr
one
cytoplasm
prr
specif
conserv
ligand
associ
cellular
damag
danger
associ
molecular
pattern
damp
invad
pathogen
pathogen
associ
molecular
pattern
pamp
upon
stimul
danger
signal
dc
undergo
activationmatur
activ
antigenpres
phenotyp
upregul
costimulatori
membran
protein
secret
proinflammatori
cytokin
tnf
tumor
necrosi
factor
interleukin
il
recent
evid
show
three
signal
key
factor
tlymphocyt
activ
villier
et
al
demonstr
chitosan
induc
activ
dc
level
membranereceptor
recognit
chitosan
promot
activ
dc
via
mechan
upregul
membran
protein
howev
fail
elicit
robust
cytokin
product
activ
cell
indic
chitosan
alon
unabl
evok
tcell
respons
nevertheless
combin
antigen
chitosan
deriv
stimul
express
major
histocompat
complex
mhc
class
molecul
profoundli
upregul
express
costimul
molecul
name
well
secret
cytokin
led
stronger
cell
prolifer
cytotox
lymphocyt
ctl
respons
one
best
character
nlr
famili
member
nlr
famili
pyrin
domain
contain
shown
associ
potent
inflammatori
respons
activ
multiprotein
complex
compos
adaptor
apoptosisassoci
specklik
protein
asc
proteas
fig
current
chitosan
particl
proven
trigger
potent
adapt
inflammatori
respons
pathway
facilit
recruit
neutrophil
proton
amino
group
proton
spong
effect
lead
extens
inflow
ion
water
lysosom
caus
osmot
swell
deconstruct
lysosom
entrap
compon
csp
ag
releas
final
present
onto
mhc
cytoplasm
degrad
proteosom
er
involv
ruptur
lysosom
enzym
cathepsin
b
also
leak
cytoplasm
induc
assembl
activ
complex
capac
stimul
csp
also
play
import
role
intracellular
synthesi
pro
trigger
secret
inflammatori
respons
togeth
activ
ag
antigen
csp
chitosan
particl
matur
apc
creat
proinflammatori
environ
character
secret
cytokin
shown
fig
disrupt
lysosom
thought
trigger
chitosanparticleinduc
respons
ruptur
leakag
lysosom
enzym
cathepsin
b
prompt
assembl
activ
complex
stimul
secret
subsequ
inflammatori
respons
recent
research
suggest
activ
inflammasom
chitosan
particl
csp
depend
upon
physiochem
properti
csp
particl
size
charg
surfac
textur
neumann
et
al
found
posit
charg
chitosan
nanoparticl
alum
induc
signific
secret
preincub
lp
activ
vitro
cellular
immun
caus
cd
tcell
activ
vital
success
prophylact
therapeut
vaccin
typic
exogen
antigen
endocytos
profession
antigen
present
cell
apc
degrad
short
peptid
within
endosom
degrad
peptid
load
onto
mhc
class
ii
molecul
present
antigen
helper
cell
lead
humor
immun
intracellular
antigen
would
escap
endosom
present
lymphocyt
mhc
class
pathway
stimul
cellular
immun
respons
tradit
adjuv
system
use
alum
fail
elicit
potent
cellular
immun
hand
chitosan
particl
possess
robust
capac
elicit
crosspresent
exogen
antigen
induc
potent
cellular
immun
respons
crosspresent
induc
sever
mean
tlr
activ
mannos
receptormedi
uptak
upregul
express
heat
shock
protein
case
csp
tune
cellular
traffick
antigen
trigger
lysosom
escap
pathway
indic
intern
chitosan
particl
disrupt
lysosom
escap
cytoplasm
proton
spong
effect
shown
fig
proton
amino
group
present
chitosan
chain
lead
extens
inflow
ion
water
lysosom
proton
spong
effect
becom
strong
enough
entrap
compon
csp
antigen
releas
ruptur
lysosom
escap
exogen
antigen
crosspres
mhc
class
pathway
like
endogen
antigen
prime
cell
evok
robust
ctl
respons
briefli
mucos
surfac
construct
singl
layer
epitheli
cell
join
tight
junction
act
natur
barrier
protect
bodi
outsid
world
pathogen
frequent
breach
epitheli
barrier
epitheli
tissu
activ
serv
sensor
detect
danger
signal
patternrecognit
receptor
tlr
respond
releas
chemokin
cytokin
recruit
maltresid
immunocyt
trigger
innat
adapt
immun
respons
recent
chitosanbas
adjuv
system
proven
mucoadhes
qualiti
uniqu
abil
open
tight
junction
epitheli
cell
natur
portal
stimul
robust
mucos
immun
respons
facilit
transport
antigen
via
altern
yet
effect
rout
antigen
deliveri
numer
studi
confirm
mucoadhes
properti
chitosan
prolong
resid
time
formul
mucos
site
includ
nasal
mucosa
gastrointestin
surfac
rectal
genit
tract
group
employ
vivo
imag
system
evalu
abil
thermosensit
htcc
hydrogel
prolong
resid
time
label
antigen
nasal
caviti
shown
fig
fluoresc
signal
detect
group
h
post
administr
howev
strong
fluoresc
intens
could
observ
group
administ
antigen
persist
nasal
caviti
h
fig
show
abil
chitosan
offer
sustain
antigenmucos
interact
without
clear
away
distinguish
trait
chitosan
mimic
pathogen
entri
open
tight
junction
epitheli
cell
also
investig
recent
research
artursson
group
suggest
abil
open
junction
due
posit
charg
amino
group
posit
chitosan
could
interact
neg
charg
mucos
surfac
anoth
studi
compar
differ
transport
c
mannitol
among
three
chitosanderiv
solut
includ
chitosan
hydrochlorid
chitosan
glutam
tmc
similar
degre
deacetyl
intestin
epitheli
cell
line
transport
c
mannitol
increas
chitosan
hydrochlorid
chitosan
glutam
tmc
wv
concentr
vitro
compar
administr
mannitol
alon
determin
chang
transepitheli
electr
resist
indic
tight
junction
use
confoc
laser
scan
microscopi
vitro
demonstr
interact
chitosan
zona
occluden
zo
protein
regard
target
chitosan
deriv
hsu
et
al
elucid
signal
mechan
underli
open
tight
junction
chitosan
cell
monolay
shown
fig
cascad
tightjunct
open
accompani
cluster
integrin
v
along
cell
peripheri
led
phosphoryl
focal
adhes
kinas
fak
also
known
protein
tyrosin
kinas
src
famili
nonspecif
tyrosin
kinas
also
result
regul
tightjunct
permeabl
via
redistribut
tightjunct
protein
cell
membran
cytosol
eventu
degrad
lysosom
preclin
clinic
research
chitosan
deriv
demonstr
lowtox
mucoadhes
capabl
abil
enhanc
intern
antigen
apc
immunestimulatori
properti
make
promis
candid
effect
mucos
adjuv
current
evid
support
chitosan
potent
mucos
adjuv
summar
recapitul
tabl
multitudin
array
vaccin
formul
differ
chitosan
type
dosag
form
model
anim
rout
administr
follow
section
applic
adjuv
system
base
chitosan
signal
mechan
csmediat
tj
open
deriv
review
regard
rout
administr
sinc
adopt
widespread
administr
sabin
oral
polio
vaccin
opv
oral
deliveri
consid
prefer
rout
administr
vaccin
especi
children
recent
chitosan
extens
studi
promis
candid
oral
administr
promot
intern
antigen
activ
system
mucos
immun
sever
studi
demonstr
associ
antigen
csp
enhanc
uptak
cell
reduc
risk
vaccin
degrad
van
der
lubben
et
al
report
size
microparticl
mp
effici
uptak
cell
also
found
fluoresc
label
chitosan
mp
taken
cell
peyer
patch
intestin
surfac
later
research
van
der
lubben
et
al
show
antigen
releas
mp
uptak
cell
moreov
dosedepend
immun
reaction
reveal
mice
vaccin
differ
dose
antigen
associ
chitosan
mp
prove
abil
chitosan
promot
intern
vaccin
aid
enter
coat
chitosan
deliveri
system
protect
stomach
acid
releas
within
enter
coat
reach
intestin
hori
et
al
develop
ovalbumin
ova
contain
chitosan
mp
chiova
coat
eudragit
erchiova
compar
uncoat
chiova
deliveri
system
significantli
higher
intestin
mucos
iga
system
igg
respons
detect
oral
administr
coat
chiova
anoth
studi
cho
et
al
present
mucoadhes
phsensit
thiolat
eudragitco
chitosan
microparticl
enhanc
capac
retain
structur
integr
encapsul
protein
recent
hbsagload
chitosan
microparticl
formul
overcom
limit
impos
enzymat
degrad
permeat
barrier
bacitracin
introduc
proteas
inhibitor
result
better
protect
level
immun
oral
administr
compar
aprotinin
proteas
inhibitor
moreov
mp
remain
stabl
room
temperatur
four
month
nasal
rout
excel
altern
convent
form
vaccin
effect
induc
system
mucos
immun
upper
lower
respiratori
tract
also
gastric
genit
tract
via
crossprotect
mention
chitosanbas
adjuv
system
provid
effect
immun
stimul
potent
enhanc
antigen
retent
mucos
permeabl
cellular
uptak
protect
antigen
well
good
safeti
profil
past
year
wit
wide
applic
chitosanbas
adjuv
preclin
research
intranas
vaccin
vila
et
al
prepar
tetanu
toxoidencapsul
chitosan
nanoparticl
intranas
antigen
deliveri
system
result
increas
longlast
humor
immun
respons
igg
iga
level
control
releas
antigen
chitosan
particl
anoth
import
factor
contribut
adjuvant
mokarram
et
al
demonstr
effect
peg
polyethylen
glycol
modif
immunestimul
perform
chitosan
nanoparticl
use
diphtheria
toxoidload
chitosan
nanoparticl
without
peg
modif
cspeg
cs
studi
cspeg
cs
nanoparticl
elicit
profoundli
higher
iga
igg
level
compar
fluid
antigen
addit
perform
cspeg
adjuv
significantli
better
may
due
control
releas
antigen
et
al
propos
novel
spraydri
steril
vaccin
outstand
stabil
intranas
administr
influenza
nonhuman
primat
employ
chitosan
stabil
protect
solut
sp
chitosan
formul
serv
induc
immun
also
stabil
antigen
especi
combin
sp
seroconvers
result
reveal
effect
pilot
formul
compar
pandemrix
moreov
hemagglutinationinhibit
titer
group
administ
steril
vaccin
show
differ
group
administ
unsteril
vaccin
chitosan
deriv
tmc
cg
chitosan
hydrochlorid
salt
also
employ
intranas
deliveri
antigen
group
develop
thermosensit
hydrogel
formul
chitosan
deriv
htcc
intranas
vaccin
deliveri
system
split
antigen
hydrogel
design
gelat
short
time
bodi
temperatur
surfac
nasal
mucosa
significantli
reduc
mucociliari
clearanc
prolong
antigen
resid
time
nasal
caviti
use
confoc
laser
scan
microscopi
scan
electron
microscopi
observ
stain
nasal
epithelia
intranas
administr
chitosan
hydrogel
provid
signific
evid
disorgan
protein
nasal
epitheli
tissu
thermosensit
hydrogel
facilit
transport
antigen
submucosa
via
paracellular
pathway
rather
endocytosi
pathway
fig
employ
intranas
deliveri
split
antigen
adenoviru
antigen
hydrogel
system
enhanc
robust
serum
mucos
antibodi
level
secret
cytokin
potent
respons
antigenspecif
memori
cell
chitosan
deriv
ad
hybrid
system
increas
adjuvant
biodegrad
polym
observ
jaganathan
et
al
report
intranas
administr
chitosan
hydrochloridemodifi
plga
mp
led
significantli
higher
antihbsag
igg
iga
titer
level
cytokin
spleen
homogen
unmodifi
plga
mp
anoth
studi
pawar
et
al
prepar
uncoat
plga
nanoparticl
chitosanmodifi
plga
np
csplga
glycol
chitosanmodifi
plga
np
gcplga
encapsul
antigen
administ
via
nasal
tract
result
show
gcplga
exhibit
highest
level
mucu
adhes
elicit
highest
igg
iga
titer
well
secret
vicent
et
al
develop
polymeroilbas
corecorona
nanocapsul
formul
oili
core
miglyol
neutral
oil
compos
triglycerid
medium
chain
fatti
acid
posit
charg
shell
chitosan
codeliveri
rhbsag
antigen
agonist
imiquimod
vaccin
orchestr
greater
secret
proinflammatori
cytokin
increas
igg
level
time
boost
cellular
humor
immun
chitosanbas
adjuv
system
also
employ
mucos
vaccin
via
rout
chen
et
al
develop
novel
transderm
deliveri
system
consist
embedd
chitosan
microneedl
support
array
compos
polylact
acid
pla
polym
sustain
deliveri
encapsul
antigen
case
ova
chitosan
microneedl
remain
epidermi
dermi
depth
approxim
day
chitosan
degrad
fig
antibodi
level
significantli
higher
microneedl
group
intramuscularadministr
group
pulmonari
administr
microparticl
contain
diphtheria
toxoid
dt
chitosan
prepar
use
spraydri
techniqu
supercrit
mixtur
carbon
dioxid
co
ethanol
immun
strong
immun
respons
observ
group
receiv
chitosandt
higher
igm
igg
titer
group
receiv
alumabsorb
dt
support
potenti
chitosan
potent
deliveri
system
pulmonari
vaccin
food
industri
chitosan
design
generallyrecognizedassaf
gra
us
japan
itali
howev
chitosan
still
util
market
vaccin
formul
studi
publish
clinic
applic
chitosan
adjuv
mill
et
al
report
safeti
immunestimulatori
capac
chitosanglutam
intranas
deliveri
system
diphtheria
toxoid
antigen
crm
among
healthi
volunt
phase
studi
three
group
subject
administ
intranas
diphtheria
vaccin
g
crm
mg
chitosan
glutam
mg
mannitol
antigen
alon
day
alumadsorb
diphtheria
toxoid
vaccin
via
intramuscular
inject
singl
administr
day
serum
igg
iga
nasal
wash
collect
day
result
suggest
chitosan
intranas
formul
well
toler
transient
mildtomoder
advers
effect
ae
nasal
discharg
blockag
discomfort
signific
differ
circul
antibodi
titer
group
first
administr
antibodi
level
group
receiv
chitosan
intranas
boost
second
vaccin
noroviru
infect
common
caus
viral
gastroenter
human
parra
et
al
develop
noroviru
viruslik
particl
vlp
vaccin
orchestr
distinct
immun
respons
rabbit
intranas
vaccin
vaccin
nvvlp
formul
spraydri
powder
compos
chitosan
chisi
tm
noroviru
vlp
antigen
mpl
monophosphoryl
lipid
immun
enhanc
chisi
tm
drug
deliveri
technolog
base
chitosan
provid
archimed
develop
limit
phase
clinic
studi
two
random
doubleblind
control
studi
nvvlp
vaccin
perform
healthi
volunt
year
old
random
receiv
two
intranas
administr
nvvlp
act
control
interv
day
studi
g
g
g
dosag
norwalk
antigen
chitosan
alon
evalu
studi
four
group
healthi
subject
administ
mplchitosan
g
vlp
per
dose
powder
chitosan
placebo
puff
air
symptom
record
day
vaccin
safeti
evalu
follow
day
sampl
serum
peripher
blood
mononuclear
cell
also
collect
result
indic
common
symptom
nasal
stuffi
discharg
sneez
vaccinerel
seriou
advers
effect
sae
observ
signific
immun
respons
found
dose
igg
iga
titer
increas
respect
subject
receiv
vaccin
dose
g
produc
iga
antibodysecret
cell
asc
surfac
molecul
associ
home
mucos
peripher
lymphoid
tissu
integrin
integrin
result
indic
intranas
administr
nvvlp
may
evok
iga
secret
intestin
mucos
tissu
entri
site
noroviru
studi
healthi
adult
year
age
random
receiv
primari
booster
inject
either
vaccin
g
vlp
per
dose
placebo
administ
week
apart
three
week
second
inject
subject
challeng
noroviru
serolog
data
collect
clinic
efficaci
assess
occurr
infect
onset
sever
durat
ill
caus
noroviru
ae
nasal
stuffi
nasal
discharg
sneez
also
report
trial
occur
similar
frequenc
among
vaccin
placebo
recipi
signific
iga
respons
increas
detect
vaccin
recipi
moreov
occurr
norovirusinduc
gastroenter
placebo
recipi
vs
vaccin
recipi
p
viru
infect
placebo
recipi
vs
vaccin
recipi
p
significantli
reduc
nvvlp
vaccin
chitosanbas
adjuv
system
develop
versatil
formul
excel
toler
distinct
mucoadhes
robust
capac
stimul
cellular
humor
immun
clinic
preclin
studi
applic
adjuv
system
would
significantli
improv
vaccin
develop
meet
need
reduc
cost
increas
stabil
easier
administr
howev
chitosan
adjuv
system
approv
clinic
trial
ongo
clinic
experi
none
yet
includ
licens
vaccin
product
numer
challeng
still
hinder
develop
chitosanbas
mucos
adjuv
system
human
divers
type
chitosan
differ
concentr
variou
dd
mw
studi
separ
research
group
use
divers
rang
antigen
tabl
could
also
lead
controversi
confus
regard
potenti
applic
human
medicin
futur
research
need
investig
mode
action
chitosan
base
differ
aforement
properti
establish
criteria
advanc
chitosan
develop
envisag
boom
futur
chitosan
adjuv
novel
mucos
vaccin
formul
although
hurdl
still
need
overcom
reason
expect
long
chitosanbas
deliveri
system
vaccin
releas
onto
market
